Featuring an interview with Dr Lajos Pusztai, including the following topics:
- Circulating tumor DNA monitoring for patients with ER-positive, HER2-negative high-risk breast cancer during adjuvant endocrine therapy (0:00)
- Clinical performance of a whole-genome assay for predicting disease recurrence (5:52)
- Using circulating tumor DNA status to personalize CDK4/6 inhibitor therapy (12:46)
- Neoadjuvant and adjuvant therapy stratified by circulating tumor DNA status (21:11)
- Utility of circulating tumor DNA status in the management of metastatic breast cancer (24:55)